HRID 1220728als Produkt
Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
871351-60-9CCN1CCC(c2cccc(S(C)(=O)=O)c2F)CC1UKUPJASJNQDHPH-UHFFFAOYSA-NACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects. ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.
871351-60-9DTXSID60236146CHEMBL3545010ACR325 is a dopaminergic stabiliser. The compound significantly increases the level of dopamine and noradrenalin in the forebrain and concurrently inhibits the over-activity of dopamine in other regions of the brain without unwanted inhibitory effect on motor activity.